# Ascentage Pharma Group Internat (AAPG)

> Source: Nexqual · https://nexqual.com/AAPG · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Ascentage Pharma Group Internat (AAPG), nexqual.com/AAPG" · informational, not investment advice.

**Price:** USD 14.69 (-1.08% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 14.85 · day 14.47–14.93 · 52w 14.46–35.86 · market cap $1.37B · NGM

## Key facts
- Analysts: Buy (mean 1.70 on a 1–5 scale) (10 analysts), mean target USD 44.5 (range 33–55).
- Total return with dividends: 1Y -59.7% vs S&P 500 +18.1%; 5Y -15.5% vs S&P 500 +85.1%.
- Next earnings: 2026-08-19, EPS estimate USD -0.56, revenue estimate $178M.

## Analysts
Consensus Buy (mean 1.70 on a 1–5 scale), 10 analysts; mean target USD 44.5 (low 33, high 55).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Citigroup | Initiated | Buy | $46 |
| 2026-10-13 | Citizens | Initiated | Market Outperform | $35 |
| 2026-10-08 | JP Morgan | Target lowered | Overweight | $46 → $33 |
| 2026-08-21 | BTIG | Reiterated | Buy | $48 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2025-01-20) |
|---|---|---|
| Total return | -59.7% | -15.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -59.8% | -9.2% |
| Volatility (annualized) | 59.0% | 64.7% |
| Max drawdown | -60.1% (Oct 2025→Oct 2026) | -69.3% (Aug 2025→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/AAPG · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt